Advertisement

EAS 2017 Congress Prague highlights

      EAS Congress Prague, held during 23–26 April 2017, broke all previous records with almost 2500 delegates attending this premier event. The Congress featured topical ‘state-of-the-art’ plenaries, novel therapeutic approaches in managing elevated cholesterol and triglycerides, as well as insights into how genetics impacts dietary approaches for preventing cardiometabolic disease. Here we provide a snapshot of some of the highlights.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Murphy A.J.
        • Tall A.R.
        Disordered haematopoiesis and athero-thrombosis.
        Eur. Heart J. 2016; 37: 1113-1121
        • Tall A.R.
        • Levine R.L.
        Cardiovascular disease: commonality with cancer.
        Nature. 2017; 543: 45-47
        • Hill A.B.
        The environment and disease. Association or causation?.
        Proc. R. Soc. Med. 1965; 58: 295-300
        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • et al.
        Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society.
        Eur. Heart J. 2013; 34: 3478-3490
        • Ference B.A.
        • Ginsberg H.N.
        • Graham I.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur. Heart J. 2017 Apr 24; ([Epub ahead of print])https://doi.org/10.1093/eurheartj/ehx144
        • Yusuf S.
        • Hawken S.
        • Ounpuu S.
        • et al.
        Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
        Lancet. 2004; 364: 937-952
        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N. Engl. J. Med. 2017; 376: 1713-1722
        • Ridker P.M.
        • Revkin J.
        • Amarenco P.
        • et al.
        Cardiovascular efficacy and safety of bococizumab in high-risk patients.
        N. Engl. J. Med. 2017; 376: 1527-1539
        • Wiegman A.
        • Gidding S.S.
        • Watts G.F.
        • et al.
        Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
        Eur. Heart J. 2015; 36: 2425-2437
        • Nicholls S.J.
        • Puri R.
        • Anderson T.
        • et al.
        Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.
        JAMA. 2016; 316: 2373-2384
        • Giugliano R.P.
        • Wiviott S.D.
        • Blazing M.A.
        • et al.
        Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : a prespecified analysis of the IMPROVE-IT trial.
        JAMA Cardiol. 2017 Mar 14; ([Epub ahead of print])https://doi.org/10.1001/jamacardio.2017.0083
        • Descamps O.S.
        • Bruniaux M.
        • Guilmot P.F.
        • Tonglet R.
        • Heller F.R.
        Lipoprotein concentrations in newborns are associated with allelic variations in their mothers.
        Atherosclerosis. 2004; 172: 287-298
        • Dietschy J.M.
        • Turley S.D.
        Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal.
        J. Lipid Res. 2004; 45: 1375-1397
        • Gaudet D.
        • Digenio A.
        • Alexander V.
        • et al.
        The APPROACH study: a randomized, double-blind, placebo-controlled, Phase 3 study of volvanesorsen administered subcutaneously to patients with familial chylomicronaemia syndrome (FCS).
        Atherosclerosis. 2017; (in press)
        • Gaudet D.
        • Gipe D.
        • Hovingh G.K.
        • et al.
        Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolaemia; a single arm, open-label, proof of concept study.
        Atherosclerosis. 2016; 252: e254-e255
        • Bray M.S.
        • Loos R.J.
        • McCaffery J.M.
        • et al.
        NIH working group report-using genomic information to guide weight management: from universal to precision treatment.
        Obesity. 2016; 24: 14-22
        • Wang T.
        • Huang T.
        • Zheng Y.
        • et al.
        Genetic variation of fasting glucose and changes in glycemia in response to 2-year weight-loss diet intervention: the POUNDS LOST trial.
        Int. J. Obes. (Lond). 2016; 40: 1164-1169